Global Vaccine Contract Manufacturing Market

Vaccine Contract Manufacturing Market

  • CM-2116
  • 4.5 Rating
  • 188 Pages
  • Upcoming
  • 84 Reviews
  • PDF Excel PPT
Raksha

Author:

Raksha Sharma

Vineet

Fact-checked by:

Vineet Pandey

Rucha

Editor:

Rucha Phatak

Vaccine Contract Manufacturing Market Outlook 2031:

The global vaccine contract manufacturing market size was valued at USD 2.84 Billion in 2022 and is expected to reach USD 7.37 Billion by 2031 projected to expand at a CAGR of 11.18% during the forecast period, 2023 – 2031The growth of the market is attributed to owing to the rising demand for vaccines for the treatment and prevention from diseases.

Vaccines manufacturing is a process of developing and preparation of potential drugs for the treatment of diseases where expertise in the field is required. Apart from ensuring the safety and effectiveness of the treatment of disease, the vaccines produced are aimed at preventing or annihilation of diseases infection. The market is largely influenced by the rise of chronic illness and infectious diseases, which are varied from one country to other.

Vaccine Contract Manufacturing Market Outlook

Massive expenditures in the installation and development of equipment, facilities, and hiring skilled labor that seeks to continue localize supply of essential materials and components for vaccines are some key factors expected to influence the acceptance of contract services.

Moreover, certain countries need to update their equipment for manufacturing that requires them to indulge in partnerships with contract manufacturers to meet market demand. Increase in the number of product pipeline has fueled the demand for outsourcing services to decrease the timeline for their entry. Small scale and large scale firms are observed to be outsourcing to develop product pipeline at low cost.

Vaccine Contract Manufacturing Market Trends, Drivers, Restraints, and Opportunities

  • Wide prevalence of infectious diseases and chronic illness along with the increasing number of the aging population globally is expected to boost the vaccine contract manufacturing market growth.
  • Increasing awareness about vaccination and its benefits to cure and prevent from disease among a large number of people in developing countries is further anticipated to spur the global vaccine contract manufacturing market expansion.
  • Favorable government policies to expand regular immunization programs for children and infants presents a key driving factor of the vaccine contract manufacturing market.
  • Growing concerns for complications and financial requirement for vaccine production have pushed to focus on contract services for vaccine manufacturing. This is projected to propel the vaccine contract manufacturing market expansion.   
  • Requirement of huge investments in equipment, facilities, and hiring skilled labor are some of the major restraining factors that can hamper the vaccine contract manufacturing market growth.

Scope of Vaccine Contract Manufacturing Market Report                          

The report on the global vaccine contract manufacturing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Vaccine Contract Manufacturing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2022

Historic Data

2016–2021

Forecast Period

2016–2031

Segmentation

Vaccine Types (Attenuated, Inactivated, Subunit-based, Toxoid-based, and DNA-based), Workflows (Downstream [Packaging, Analytical & QC Studies, And Fill & Finish Operations], Upstream [Yeast Expression Systems, Bacterial Expression Systems, Mammalian Expression Systems, Baculovirus/Insect Expression Systems, And Others]), and Applications (Human Use and Veterinary)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Lonza Group; FUJIFILM Diosynth Biotechnologies U.S.A., Inc.; Ajinomoto Bio-Pharma Services, Inc.; Merck KGaA; Cytovance Biologics, Inc.; Catalent, Inc.; IDT Biologika GmbH; Albany Molecular Research, Inc.; PRA Health Sciences; ICON plc.; Pharmaceutical Product Development, LLC; Cobra Biologics; and Paragon Bioservices, Inc.

Vaccine Contract Manufacturing Market Segment Insights

Attenuated segment is expected to grow at a rapid pace

Based on vaccine types, the global vaccine contract manufacturing market is divided into attenuated, inactivated, subunit-based, toxoid-based, and DNA-based. The attenuated segment is expected to grow at a rapid pace in the coming years owing to wide approval of large number of the vaccine types.

However, the inactivated segment is anticipated to account for a key market share during the forecast period as they are safer and stable than other vaccine types
.

Vaccine Contract Manufacturing Market Vaccine Type

Downstream segment is projected to expand at a considerable CAGR

On the basis of workflows, the global vaccine contract manufacturing market is bifurcated into downstream and upstream. The downstream segment is further divided into packaging, analytical & QC studies, and fill & finish operations. The upstream segment consists of yeast expression systems, bacterial expression systems, mammalian expression systems, baculovirus/insect expression systems, and others.

The downstream segment is projected to expand at a considerable CAGR during the forecast period owing to a high requirement for biotechnological tools and skilled personnel. Meanwhile, the upstream segment is anticipated to constitute a considerable market share during the forecast period due to advancements in bioprocessing techniques.

Human use segment is expected to exhibit a robust growth rate

Based on applications, the global vaccine contract manufacturing market is bifurcated into human use and veterinary. The human use segment is expected to exhibit a robust growth rate during the targeted period owing to wide range of illness and disease infections in humans.

On the other hand, the veterinary segment is anticipated to expand at a healthy CAGR during the forecast period due to increase in the demand for animal-based vaccines.

Vaccine Contract Manufacturing Market Application

North America is anticipated to constitute a key market share

In terms of regions, the global vaccine contract manufacturing market share is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to constitute a key share of the market in the coming years owing to widespread manufacturing of vaccines in the region.

The market of Asia Pacific, however, is anticipated to grow significantly during the forecast period due to improving infrastructure and regulatory changes related to vaccine manufacturing and entering business contracts.

Vaccine Contract Manufacturing Market Region

Segments

The global vaccine contract manufacturing market has been segmented on the basis of

Vaccine Types

  • Attenuated
  • Inactivated
  • Subunit-based
  • Toxoid-based
  • DNA-based

Workflow

  • Downstream
    • Packaging
    • Analytical & QC Studies
    • Fill & Finish Operations
  • Upstream
    • Yeast Expression Systems
    • Bacterial Expression Systems
    • Mammalian Expression Systems
    • Baculovirus/Insect Expression Systems
    • Others

Applications

  • Human Use
  • Veterinary

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

Competitive Landscape

Key players competing in the vaccine contract manufacturing market are Lonza Group; FUJIFILM Diosynth Biotechnologies U.S.A., Inc.; Ajinomoto Bio-Pharma Services, Inc.; Merck KGaA; Cytovance Biologics, Inc.; Catalent, Inc.; IDT Biologika GmbH; Albany Molecular Research, Inc.; PRA Health Sciences; ICON plc.; Pharmaceutical Product Development, LLC; Cobra Biologics; and Paragon Bioservices, Inc. The main market players are continuously engaged in activities such as mergers and acquisitions, research and developments, investments for innovative products, and collaborations.

Vaccine Contract Manufacturing Market Key Players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Vaccine Contract Manufacturing Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Vaccine Contract Manufacturing Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Vaccine Contract Manufacturing Market - Supply Chain
  4.5. Global Vaccine Contract Manufacturing Market Forecast
     4.5.1. Vaccine Contract Manufacturing Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Vaccine Contract Manufacturing Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Vaccine Contract Manufacturing Market Absolute $ Opportunity
5. Global Vaccine Contract Manufacturing Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Vaccine Contract Manufacturing Market Size and Volume Forecast by Types
     5.3.1. Attenuated
     5.3.2. Inactivated
     5.3.3. Subunit-based
     5.3.4. Toxoid-based
     5.3.5. DNA-based
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Vaccine Contract Manufacturing Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Vaccine Contract Manufacturing Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Vaccine Contract Manufacturing Demand Share Forecast, 2019-2026
7. North America Vaccine Contract Manufacturing Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Vaccine Contract Manufacturing Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Vaccine Contract Manufacturing Market Size and Volume Forecast by Types
     7.4.1. Attenuated
     7.4.2. Inactivated
     7.4.3. Subunit-based
     7.4.4. Toxoid-based
     7.4.5. DNA-based
  7.5. Basis Point Share (BPS) Analysis by Types
  7.6. Y-o-Y Growth Projections by Types
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Vaccine Contract Manufacturing Demand Share Forecast, 2019-2026
8. Latin America Vaccine Contract Manufacturing Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Vaccine Contract Manufacturing Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Vaccine Contract Manufacturing Market Size and Volume Forecast by Types
     8.4.1. Attenuated
     8.4.2. Inactivated
     8.4.3. Subunit-based
     8.4.4. Toxoid-based
     8.4.5. DNA-based
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Vaccine Contract Manufacturing Demand Share Forecast, 2019-2026
9. Europe Vaccine Contract Manufacturing Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Vaccine Contract Manufacturing Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Vaccine Contract Manufacturing Market Size and Volume Forecast by Types
     9.4.1. Attenuated
     9.4.2. Inactivated
     9.4.3. Subunit-based
     9.4.4. Toxoid-based
     9.4.5. DNA-based
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Vaccine Contract Manufacturing Demand Share Forecast, 2019-2026
10. Asia Pacific Vaccine Contract Manufacturing Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Vaccine Contract Manufacturing Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Vaccine Contract Manufacturing Market Size and Volume Forecast by Types
     10.4.1. Attenuated
     10.4.2. Inactivated
     10.4.3. Subunit-based
     10.4.4. Toxoid-based
     10.4.5. DNA-based
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Vaccine Contract Manufacturing Demand Share Forecast, 2019-2026
11. Middle East & Africa Vaccine Contract Manufacturing Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Vaccine Contract Manufacturing Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Vaccine Contract Manufacturing Market Size and Volume Forecast by Types
     11.4.1. Attenuated
     11.4.2. Inactivated
     11.4.3. Subunit-based
     11.4.4. Toxoid-based
     11.4.5. DNA-based
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Vaccine Contract Manufacturing Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Vaccine Contract Manufacturing Market: Market Share Analysis
  12.2. Vaccine Contract Manufacturing Distributors and Customers
  12.3. Vaccine Contract Manufacturing Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Lonza Group
     12.4.2. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
     12.4.3. Ajinomoto Bio-Pharma Services, Inc.
     12.4.4. Merck KGaA
     12.4.5. Cytovance Biologics, Inc.
     12.4.6. Catalent, Inc.
     12.4.7. IDT Biologika GmbH

Purchase Premium Report